Motor neuron diseases (MNDs) include a broad group of diseases in which neurodegeneration mainly affects upper and/or lower motor neurons (MNs). Although the involvement of specific MNs, symptoms, age of onset, and progression differ in MNDs, the main pathogenic mechanism common to most MNDs is represented by proteostasis alteration and proteotoxicity. This pathomechanism may be directly related to mutations in genes encoding proteins involved in the protein quality control system, particularly the autophagy-lysosomal pathway (ALP). Alternatively, proteostasis alteration can be caused by aberrant proteins that tend to misfold and to aggregate, two related processes that, over time, cannot be properly handled by the ALP. Here, we summarize the main ALP features, focusing on different routes utilized to deliver substrates to the lysosome and how the various ALP pathways intersect with the intracellular trafficking of membranes and vesicles. Next, we provide an overview of the mutated genes that have been found associated with MNDs, how these gene products are involved in different steps of ALP and related processes. Finally, we discuss how autophagy can be considered a valid therapeutic target for MNDs treatment focusing on traditional autophagy modulators and on emerging approaches to overcome their limitations.

The role of autophagy-lysosomal pathway in motor neuron diseases / B. Tedesco, V. Ferrari, M. Cozzi, M. Chierichetti, E. Casarotto, P. Pramaggiore, F. Mina, M. Piccolella, R. Cristofani, V. Crippa, P. Rusmini, M. Galbiati, A. Poletti. - In: BIOCHEMICAL SOCIETY TRANSACTIONS. - ISSN 0300-5127. - 50:5(2022 Oct), pp. 1489-1503. [10.1042/BST20220778]

The role of autophagy-lysosomal pathway in motor neuron diseases

B. Tedesco
Co-primo
;
V. Ferrari
Co-primo
;
M. Cozzi;M. Chierichetti;E. Casarotto;P. Pramaggiore;F. Mina;M. Piccolella;R. Cristofani;V. Crippa;P. Rusmini;M. Galbiati
Penultimo
;
A. Poletti
Ultimo
2022

Abstract

Motor neuron diseases (MNDs) include a broad group of diseases in which neurodegeneration mainly affects upper and/or lower motor neurons (MNs). Although the involvement of specific MNs, symptoms, age of onset, and progression differ in MNDs, the main pathogenic mechanism common to most MNDs is represented by proteostasis alteration and proteotoxicity. This pathomechanism may be directly related to mutations in genes encoding proteins involved in the protein quality control system, particularly the autophagy-lysosomal pathway (ALP). Alternatively, proteostasis alteration can be caused by aberrant proteins that tend to misfold and to aggregate, two related processes that, over time, cannot be properly handled by the ALP. Here, we summarize the main ALP features, focusing on different routes utilized to deliver substrates to the lysosome and how the various ALP pathways intersect with the intracellular trafficking of membranes and vesicles. Next, we provide an overview of the mutated genes that have been found associated with MNDs, how these gene products are involved in different steps of ALP and related processes. Finally, we discuss how autophagy can be considered a valid therapeutic target for MNDs treatment focusing on traditional autophagy modulators and on emerging approaches to overcome their limitations.
HSPB8; ALS; SBMA; Kennedy’s disease; androgen; motoneuron diseases; chaperone; proteasome; autophagy; aggregation; misfolding; casa
Settore BIO/13 - Biologia Applicata
Settore BIO/09 - Fisiologia
   RAN translation of normal and expanded nucleotide repeat containing transcripts to neurotoxic polypetides in neurodegenerative diseases
   No RAn for old man
   FONDAZIONE CARIPLO
   2014-0686

   Selective translation of androgen receptor isoform A to prevent polyQ mediated toxicity in Kennedy’s disease
   MLOMALS
   KENNEDY'S DISEASE ASSOCIATION

   Alternative translation initiation as a novel strategy to block toxicity of the mutant Androgen Receptor in SBMA
   Co-ALS
   FONDAZIONE TELETHON ETS
   GGP19128

   Unveiling regenerative and metabolic features of SBMA muscle cells to identify new therapeutic targets
   EX_ALS
   KENNEDY'S DISEASE ASSOCIATION

   The involvement of the small heat shock protein HSPB8 in amyotrophic lateral sclerosis
   TEAM
   AFM-TELETHON - ASS. FRANCAISE CONTRE LES MYOPATHIES

   Membrane-less organelle pathology in ALS: identification of causes and rescuing factors (MLOMALS)
   MLOMALS
   FONDAZIONE ITALIANA DI RICERCA PER LA SLA - SCLEROSI LATERALE AMIOTROFICA - ARISLA

   Colchicine for Amyotrophic Lateral Sclerosis: a phase II, randomized, double blind, placebo controlled, multicenter clinical trial (Co-ALS)
   Co-ALS
   AGENZIA ITALIANA DEL FARMACO - AIFA
   AIFA-2016-02364678

   The interplay between the “rna/protein quality control system” and “exosomes” as a spreading mechanism in amyotrophic lateral sclerosis (EX_ALS)
   EX_ALS
   MINISTERO DELL'ISTRUZIONE E DEL MERITO
   2017F2A2C5_001

   Role of TDP-43 self-assembly in health and disEase: molecular characteristics, cellular Aspects and animal Models
   TEAM
   MINISTERO DELL'ISTRUZIONE E DEL MERITO
   2020PBS5MJ_005

   Role of CHIP/STUB1 in the clearance of toxic proteins responsible for repeat expansion neurodegenerative diseases
   FONDAZIONE CARIPLO
   2021-1544
ott-2022
16-set-2022
Article (author)
File in questo prodotto:
File Dimensione Formato  
bst-2022-0778c.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 2.6 MB
Formato Adobe PDF
2.6 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/938047
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact